The Journal of Bone and Joint Surgery (American) 86:1153-1160 (2004)
© 2004 The Journal of Bone and Joint Surgery, Inc.
Treatment of Osteonecrosis of the Femoral Head with Implantation of Autologous Bone-Marrow Cells
A Pilot Study
Valérie Gangji, MD1,
Jean-Philippe Hauzeur, MD, PhD1,
Celso Matos, MD1,
Viviane De Maertelaer, PhD2,
Michel Toungouz, MD, PhD1 and
Micheline Lambermont, PharmD1
1 Department of Rheumatology and Physical Medicine (V.G. and J.-P.H.),
Department of Radiology (C.M.), and the Cellular and Molecular Therapy Unit
(M.T. and M.L.), Erasme University Hospital, 808 Route de Lennik, 1070
Brussels, Belgium. E-mail address for V. Gangji:
vgangji{at}ulb.ac.be
2 Department of Biostatistics, Institut de Recherche Interdisciplinaire en
Biologie Humaine et Moleculaire, School of Medicine, Université Libre
de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium
Investigation performed at the Department of Rheumatology and Physical
Medicine, the Department of Radiology, and the Cellular and Molecular Therapy
Unit, Erasme University Hospital, Brussels, Belgium
The authors did not receive grants or outside funding in support of their
research or preparation of this manuscript. They did not receive payments or
other benefits or a commitment or agreement to provide such benefits from a
commercial entity. No commercial entity paid or directed, or agreed to pay or
direct, any benefits to any research fund, foundation, educational
institution, or other charitable or nonprofit organization with which the
authors are affiliated or associated.
A commentary is available with the electronic versions of this article,
on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our
subscription department, at 781-449-9780, to order the CD-ROM).
Background: Aseptic nontraumatic osteonecrosis of the femoral head
is a disorder that can lead to femoral head collapse and the need for total
hip replacement. Since osteonecrosis may be a disease of mesenchymal cells or
bone cells, the possibility has been raised that bone marrow containing
osteogenic precursors implanted into a necrotic lesion of the femoral head may
be of benefit in the treatment of this condition. For this reason, we studied
the implantation of autologous bone-marrow mononuclear cells in a necrotic
lesion of the femoral head to determine the effect on the clinical symptoms
and the stage and volume of osteonecrosis.
Methods: We studied thirteen patients (eighteen hips) with stage-I
or II osteonecrosis of the femoral head, according to the system of the
Association Research Circulation Osseous. The hips were allocated to a program
of either core decompression (the control group) or core decompression and
implantation of autologous bone-marrow mononuclear cells (the
bone-marrow-graft group). Both patients and assessors were blind with respect
to treatment-group assignment. The primary outcomes studied were safety,
clinical symptoms, and disease progression.
Results: After twenty-four months, there was a significant reduction
in pain (p = 0.021) and in joint symptoms measured with the Lequesne index (p
= 0.001) and the WOMAC index (p = 0.013) within the bone-marrow-graft group.
At twenty-four months, five of the eight hips in the control group had
deteriorated to stage III, whereas only one of the ten hips in the
bone-marrow-graft group had progressed to this stage. Survival analysis showed
a significant difference in the time to collapse between the two groups (p =
0.016). Implantation of bone-marrow mononuclear cells was associated with only
minor side effects.
Conclusions: Implantation of autologous bone-marrow mononuclear
cells appears to be a safe and effective treatment for early stages of
osteonecrosis of the femoral head. Although the findings of this study are
promising, their interpretation is limited because of the small number of
patients and the short duration of follow-up. Further study is needed to
confirm the results.
Level of Evidence: Therapeutic study, Level II-1
(prospective cohort study). See Instructions to Authors for a complete
description of levels of evidence.

CiteULike Connotea Del.icio.us Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. A. Mont, G. A. Marulanda, L. C. Jones, K. J. Saleh, N. Gordon, D. S. Hungerford, and M. E. Steinberg
Systematic Analysis of Classification Systems for Osteonecrosis of the Femoral Head
J. Bone Joint Surg. Am.,
November 1, 2006;
88(suppl_3):
16 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Cui, Z. Xiao, X. Li, K. J. Saleh, and G. Balian
Use of Genetically Engineered Bone-Marrow Stem Cells to Treat Femoral Defects: An Experimental Study
J. Bone Joint Surg. Am.,
November 1, 2006;
88(suppl_3):
167 - 172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Mont, L. C. Jones, and D. S. Hungerford
Nontraumatic Osteonecrosis of the Femoral Head: Ten Years Later
J. Bone Joint Surg. Am.,
May 1, 2006;
88(5):
1117 - 1132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Gangji and J.-P. Hauzeur
Treatment of Osteonecrosis of the Femoral Head with Implantation of Autologous Bone-Marrow Cells
J. Bone Joint Surg. Am.,
March 1, 2005;
87(1_suppl_1):
106 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Letters to the Editor:
Read all Letters to the Editor
- Treatment of Osteonecrosis with Autologous Marrow Cells.
- Stefan Radke
- JBJS Online, 12 Aug 2004
[Full text]
- Dr. Gangji responds to Dr. Radke
- Valérie Gangji, et al.
- JBJS Online, 30 Nov 2004
[Full text]
|